SYD985 TREATMENT OF T-DM1 REFRACTORY CANCER PATIENTS

The present invention relates to the duocarmycin-containing antibody-drug conjugate (ADC) trastuzumab vc-seco-DUBA (SYD985) for use in the treatment of trastuzumab emtansine (T-DM1) refractory HER2 IHC 3+ or HER2 IHC 2+/FISH positive cancer patients, particularly T-DM1 refractory breast cancer patie...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	KOPER, NORBERT PETER, VOORTMAN, GERRIT
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to the duocarmycin-containing antibody-drug conjugate (ADC) trastuzumab vc-seco-DUBA (SYD985) for use in the treatment of trastuzumab emtansine (T-DM1) refractory HER2 IHC 3+ or HER2 IHC 2+/FISH positive cancer patients, particularly T-DM1 refractory breast cancer patients. La présente invention concerne le conjugué anticorps-médicament (ADC) contenant de la duocarmycine trastuzumab vc-seco-DUBA (SYD985) pour une utilisation de trastuzumab emtansine (T-DM1) dans le traitement de patients atteints d'un cancer HER2 IHC 3+ ou HER2 IHC 2+/FISH positifs, en particulier chez des patients atteints d'un cancer du sein réfractaire à T-DM1.